QuantuMDx acquires identity testing services company Northgene
14 November 2012
QuantuMDx Group Limited has acquired NorthGene Limited in a transaction involving a share swap plus cash investment. The funds will be used to further develop NorthGene’s laboratory and staffing infrastructure, secure various laboratory accreditations and to expand the Company’s test portfolio and DNA analysis services to embrace medical, veterinary and scientific research applications.
NorthGene offers commercial identity testing services to the NHS, legal services and the Public. NorthGene has historically been run as a not for profit organisation under the leadership of Prof Sir John Burn, with all monies generated invested back into medical research. Elaine Warburton, QuantuMDx’s CEO said “Our aim is to continue this philanthropic philosophy of using NorthGene surpluses to invest in advancing medical research for the benefit of global health.”
NorthGene’s Managing Director Marie Whitehouse commented, “This is a wonderful opportunity for NorthGene to further expand our test portfolio under the guidance of the QuantuMDx’s scientific, quality and commercial teams, who have access to, and extensive knowledge of, the very latest proven DNA based tests across medical and non-medical applications. In time we anticipate further supporting QuantuMDx in trials and the commercial roll-out of its ground-breaking diagnostic and sequencing devices”.